The European MDR: Impetus, Impacts, And Current Status

The MDD’s Shortcomings

Adopted in the early 1990s, the MDD are composed of three directives: the Supplementary Directive for In Vitro Devices, the Supplementary Directive for Implantable Devices, and the Primary Medical Device Directive. Although the MDD served their purpose well and played a significant role in the success of the European medical device market over the past three decades, the Directives’ weaknesses have rendered them somewhat ineffective in today’s medtech world:

  • Outdated regulations: The MDD did not keep up with technological developments (and the regulatory challenges they incur) in the medical device space, particularly as it relates to hybrid devices and medical software.
  • Lack of consistency: Because the MDD were directives (as opposed to regulations), they did not supersede the laws of individual countries; as a result, there was some variation in how they were implemented across the various member states.
  • Focus on approval, not postmarket performance: Following approval under the MDD, device performance was not tracked in a particularly useful or accessible way, and continued clinical assessment was not mandatory.
  • Narrowly focused accountability: Liability for device issues and failures fell on the original manufacturer, without accounting for other companies in the supply/distribution chain; this led to a lack of accountability for other parties involved in the supply of medical devices.
  • Insufficient scrutiny on notified bodies: Notified bodies had (NBs) focused on one-time/premarket assessments and approval, behaving as industry partners for manufacturers, focusing on approval rather than device safety and quality.
Next Steps for Manufacturers
  • Monitor the ongoing release of guidance documents and legislative changes relevant to the MDR.
  • Conduct portfolio assessment to determine how your products will be classified under the MDR; consider whether divestment or prioritization of certain products will be necessary; ensure legacy products are recertified by the application deadline.
  • Update processes and procedures to meet MDR requirements — these activities include establishing or updating your compliance plan and quality-management systems, particularly for postmarket surveillance and postmarket clinical follow-ups.
  • Review all of your product documentation to eliminate any gaps in clinical data and technical documentation record-keeping.
  • Secure a suitable Notified Body; share your compliance plan.
  • Following product launch, ensure availability and accuracy of all required postmarket systems and documentations.
Author(s)Source
Zaid Al-NassirMed Device Online, June 3, 2020
This is a post of a scientific or business information. The information given here is checked thoroughly by “Implant-Register”. However we can´t be responsible for the content. Contact the publisher, if you have questions. You may inform us about changes of the information to improve the Register.
Comments: n/a
let us know
Scroll to Top